WASHINGTON, D.C.—Detrusor botulinum toxin type A injections are a safe and effective treatment long-term for patients with severe overactive bladder (OAB), Swiss researchers reported at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—Men and women who suffer from overactive bladder (OAB) report significantly greater levels of work limitations compared with those without urinary symptoms, according to a new study presented at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—The natural history of lower urinary tract symptoms (LUTS) and overactive bladder (OAB) may involve as much remission as progression, according to a new longitudinal study presented at the American Urological Association 2011 annual meeting.
WASHINGTON, D.C.—Overactive bladder (OAB) is highly prevalent in both women and men and the prevalence varies by race and ethnicity, according to study findings presented at the American Urological Association 2011 annual meeting.